Datroway Continues To Show Promising Tumor Responses As Part Of Combination Regimens In Patients With Early And Advanced Non-Small Cell Lung Cancer

RefinitivThời gian đọc: dưới 1 phút

Daiichi Sankyo Co Ltd 4568:

DATROWAY® CONTINUES TO SHOW PROMISING TUMOR RESPONSES AS PART OF COMBINATION REGIMENS IN PATIENTS WITH EARLY AND ADVANCED NON-SMALL CELL LUNG CANCER
DAIICHI SANKYO CO LTD - PHASE 2 RESULTS SHOW POTENTIAL FOR DATROWAY PLUS DURVALUMAB

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này